Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Technology
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Visual Stories
  • Reviews
  • Phone Reviews
  • Fitness Bands Reviews
  • Speakers Reviews
  • Find Cricket Statistics
Hindi
More
In the news
Petrol Diesel Prices
Char Dham Yatra
Gyanvapi Mosque
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Technology
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Visual Stories
Reviews
Phone Reviews
Fitness Bands Reviews
Speakers Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
India

Expert panel recommends emergency use authorization for Zydus's three-dose vaccine

Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
Written by Ramya Patelkhana
Aug 20, 2021, 07:41 pm 3 min read
Expert panel recommends emergency use authorization for Zydus's three-dose vaccine
Credits:
ZyCoV-D: CDSCO’s SEC on COVID-19 gives its nod to Zydus Cadila's three-dose COVID-19 vaccine

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting an emergency use authorization (EUA) to ZyCoV-D, the three-dose COVID-19 vaccine developed by Zydus Cadila, on Friday. Once approved by the Drug Controller General of India (DCGI), ZyCoV-D will become the first-ever plasmid DNA vaccine in the world to be used against COVID-19. Here's more.

Details
Three-dose vaccine will be administered intradermally using a needle-free injector

Zydus Cadila's ZyCoV-D is a three-dose vaccine and each dose is given 28 days apart—the second and third doses are administered 28 days and 56 days after the first dose, respectively. Moreover, the vaccine would be administered intradermally with the help of a needle-free injector. If approved for use by the DCGI, ZyCoV-D will be the second indigenous vaccine to be used in India.

Application
Zydus Cadila applied for EUA to ZyCoV-D on July 1

To recall, Ahmedabad-based Zydus Cadila had applied for the EUA from the DCGI for its COVID-19 vaccine on July 1. Earlier on Thursday, the SEC on COVID-19 had deliberated on the pharma major's application and decided to recommend granting the EUA to its ZyCoV-D. The expert panel has further sent its recommendations to the national drugs regulator for final approval.

Information
India has so far approved five COVID-19 vaccines

Once cleared for use, ZyCoV-D will become the second indigenous COVID-19 vaccine after Hyderabad-based Bharat Biotech's COVAXIN and the sixth vaccine to be approved in India. So far, India has authorized five vaccines: Covishield, COVAXIN, Sputnik V, Moderna's vaccine, and J&J's single-dose vaccine.

Trials
ZyCoV-D works against Delta variant: Zydus Cadila

According to Zydus Cadila, it has conducted the largest clinical trial for ZyCoV-D in the country in more than 50 centers so far. Notably, trials were also conducted in the 12-18 years age group. Apart from adolescents, the company is also planning to conduct trials on children aged above five years. Zydus Cadila claims its COVID-19 vaccine provides protection against the Delta variant, too.

Procedure
What is the needle-free injection system?

As mentioned before, ZyCoV-D is an intradermal vaccine administered using a needle-free injection system, which may also reduce several post-immunization side-effects. Usually, the needle-free injection procedure involves accelerating a fluid jet to high speeds so that it penetrates between the layers of the skin (intradermal) through a specialized fine-diameter nozzle. To note, all the vaccines currently being used in India are administered intramuscularly.

The vaccine
ZyCoV-D has 66% efficacy rate against symptomatic COVID-19 cases

Zydus Cadila said ZyCoV-D is 66% effective against symptomatic COVID-19 cases and has shown a 100% efficacy rate against moderate cases. It can be stored at 2-8 degrees Celsius and remains stable even at 25 degrees Celsius for up to three months. ZyCoV-D has been developed by Zydus Cadila in collaboration with the Department of Biotechnology and the Indian Council of Medical Research (ICMR).

Share this timeline
Facebook
Whatsapp
Twitter
Linkedin
Ramya Patelkhana
Ramya Patelkhana
Mail
Ramya Patelkhana is a senior editor at NewsBytes. She has nearly seven years of experience in digital journalism and has previously worked with India News and Authint Media. She has a Bachelor's degree in Journalism and Mass Communication from the IK Gujral Punjab Technical University, Kapurthala, and an advanced diploma in Media Studies from IPW, New Delhi.
Latest
Central Drugs Standard Control Organization (CDSCO)
Drugs Controller General of India
Zydus Cadila
Coronavirus
COVID-19
Related
Latest
5 most scenic rail routes in India
5 most scenic rail routes in India Lifestyle
Redmi Note 11SE debuts with MediaTek Dimensity 700 SoC
Redmi Note 11SE debuts with MediaTek Dimensity 700 SoC Technology
Top 5 biographical movies that Hollywood has churned out
Top 5 biographical movies that Hollywood has churned out Entertainment
AS Roma win UEFA Europa Conference League title: Records broken
AS Roma win UEFA Europa Conference League title: Records broken Sports
2023 Honda CR-V previewed with hybrid badge ahead of debut
2023 Honda CR-V previewed with hybrid badge ahead of debut Auto
Central Drugs Standard Control Organization (CDSCO)
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon
India: Phase-2 trials of world's first one-shot pneumococcal vaccine soon India
J&J withdraws vaccine approval request in India, CDSCO says
J&J withdraws vaccine approval request in India, CDSCO says India
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN India
Expert panel says no to Covovax's children trials in India
Expert panel says no to Covovax's children trials in India India
COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel
COVAXIN phase 2/3 trials for 2-18-year-olds recommended by expert panel India
More News
Drugs Controller General of India
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years India
COVAXIN likely to get approval for children above 2yrs: Report
COVAXIN likely to get approval for children above 2yrs: Report India
Biological E's Corbevax vaccine approved for children aged 12-18 years
Biological E's Corbevax vaccine approved for children aged 12-18 years India
COVAXIN, Covishield will now be available in hospitals and clinics
COVAXIN, Covishield will now be available in hospitals and clinics India
New anti-COVID drug may cost up to Rs. 3,000: Report
New anti-COVID drug may cost up to Rs. 3,000: Report India
More News
Zydus Cadila
Are Indian vaccines effective against Omicron? Here's what manufacturers say
Are Indian vaccines effective against Omicron? Here's what manufacturers say India
ZyCoV-D expected to be rolled out in two weeks: Report
ZyCoV-D expected to be rolled out in two weeks: Report India
Here are some key drugs being tested for COVID-19 treatment
Here are some key drugs being tested for COVID-19 treatment World
NTAGI to devise roadmap to introduce ZyCoV-D into inoculation drive
NTAGI to devise roadmap to introduce ZyCoV-D into inoculation drive India
COVID-19 vaccine for children likely by September, says ICMR-NIV chief
COVID-19 vaccine for children likely by September, says ICMR-NIV chief India
More News
Coronavirus
COVID-19: India logs 3,303 new cases; 39 more deaths
COVID-19: India logs 3,303 new cases; 39 more deaths India
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man
COVID-19 XE variant reported by Gujarat; detected in 67-year-old man India
COVID-19 vaccine precautionary dose available for 18+ from April 10
COVID-19 vaccine precautionary dose available for 18+ from April 10 India
COVID-19 survivors at risk of developing serious blood clots: Study
COVID-19 survivors at risk of developing serious blood clots: Study Technology
COVID-19: India reports 1,660 new cases, 4,100 more deaths
COVID-19: India reports 1,660 new cases, 4,100 more deaths India
More News
COVID-19
COVID-19: India logs 2,124 fresh cases, 17 more deaths
COVID-19: India logs 2,124 fresh cases, 17 more deaths India
COVID-19: India logs 1,675 fresh cases, 31 more deaths
COVID-19: India logs 1,675 fresh cases, 31 more deaths India
Pandemic created a billionaire every 30 hours: Oxfam at Davos
Pandemic created a billionaire every 30 hours: Oxfam at Davos World
First cases of new Omicron subvariants detected in India
First cases of new Omicron subvariants detected in India India
COVID-19 re-emergence: Saudi bans travel to India, 15 other countries
COVID-19 re-emergence: Saudi bans travel to India, 15 other countries World
More News
Related
Biological E-manufactured J&J's single-dose COVID-19 vaccine in India by October
Biological E-manufactured J&J's single-dose COVID-19 vaccine in India by October India
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA
US: Pfizer-BioNTech COVID-19 vaccine officially granted full approval by FDA World
COVID-19 vaccine trials for ages 3-12 soon: Zydus Cadila MD
COVID-19 vaccine trials for ages 3-12 soon: Zydus Cadila MD India
Zydus Cadila's COVID-19 vaccine approved. What you need to know
Zydus Cadila's COVID-19 vaccine approved. What you need to know India
Next News Article
Next News Article

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Technology News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Mukesh Ambani Indian Premier League (IPL) Karnataka Samsung Xiaomi West Bengal
Bihar Virat Kohli Rohit Sharma Haryana Narendra Modi Arvind Kejriwal Tamil Nadu Gujarat Yogi Adityanath YouTube
Instagram Hollywood News Uttar Pradesh Kerala Netflix Bollywood News Mamata Banerjee Maruti Suzuki Rahul Gandhi Elon Musk
Shah Rukh Khan Chelsea FC OPPO Akhilesh Yadav Indian Cricket Team Apple Manchester United Salman Khan Cryptocurrency OnePlus
Amitabh Bachchan ICC Women's World Cup Vivo India vs Sri Lanka
About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive IPL 2022 Schedule IPL 2022 Points Table Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2022